NMDA receptor antagonists: tools in neuroscience with promise for treating CNS pathologies.
Köhr
Georg
G
Department of Molecular Neurobiology, Max-Planck-Institute for Medical Research, Heidelberg, Germany. kohr@mpimf-heidelberg.mpg.de
D000818:Animals; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000473:pathology; D003915:Dextromethorphan / Q000627:therapeutic use; D016291:Dizocilpine Maleate / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007473:Ion Channels / Q000187:drug effects / Q000502:physiology; D007649:Ketamine / Q000627:therapeutic use; D008559:Memantine / Q000627:therapeutic use; D049990:Membrane Transport Modulators / Q000627:therapeutic use*; D051381:Rats; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors* / Q000502:physiology
D018691:Excitatory Amino Acid Antagonists; D007473:Ion Channels; D049990:Membrane Transport Modulators; D016194:Receptors, N-Methyl-D-Aspartate; D007649:Ketamine; D016291:Dizocilpine Maleate; D003915:Dextromethorphan; D008559:Memantine